{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "Chi Kin Law",
      "orcid": "0000-0002-2364-324X"
    },
    {
      "name": "Martin R. Stockler"
    },
    {
      "name": "Andrew J. Martin"
    },
    {
      "name": "Ian D. Davis",
      "orcid": "0000-0002-9066-8244"
    },
    {
      "name": "Christopher J. Sweeney"
    },
    {
      "name": "Rachael L. Morton"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/cgfk0y9mtfpxt.bib",
  "cited_by": 0,
  "doi": "10.1016/j.eclinm.2026.104207",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673054/?tool=EBI",
  "id": "cgfk0y9mtfpxt",
  "issns": [
    "2589-5370"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13673054",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2002|Health Systems, Economic Evaluations, Quality of Life"
    ]
  ],
  "openalex": "W7220380080",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673054/pdf/?tool=EBI",
  "pmcid": "PMC13673054",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "Elsevier BV",
  "ris": "https://research.draconitic.com/paper/cgfk0y9mtfpxt.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:29Z",
      "native_id": "PMC:PMC13673054",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13673054"
    },
    {
      "first_seen": "2026-10-30T12:19:48Z",
      "native_id": "10.1016/j.eclinm.2026.104207",
      "source": "crossref",
      "url": "https://linkinghub.elsevier.com/retrieve/pii/S2589537026004608"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:F27",
      "subfield": "general"
    }
  ],
  "title": "Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)",
  "title_text": "Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:48Z",
  "url": "https://research.draconitic.com/paper/cgfk0y9mtfpxt",
  "venue": "EClinicalMedicine",
  "versions": []
}